---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-047099"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:28:45.098446+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sangamo posts Q3 net income $10.7M; FDA clears Accelerated Approval path for Fabry gene therapy ST-920

## Summary
- Net income $10.7M ($0.04 diluted EPS) vs net loss $104.2M ($0.59 loss) in Q3 2023.
- Revenue $49.4M (up from $9.4M), driven by $49.2M from Genentech collaboration.
- FDA agrees Phase 1/2 STAAR data can support Accelerated Approval for ST-920 in Fabry disease; BLA submission expected H2 2025.
- Received $50M from Genentech upfront/milestones; eligible for up to $1.9B in additional milestones plus tiered royalties.
- Cash $39.2M; expects to fund operations into Q1 2025 including $10M milestone from Genentech.

## SEC filing metadata
- accession: 0001628280-24-047099
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828024047099/0001628280-24-047099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828024047099/sgmo-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-047099
- JSON: https://secwatch.observer/filing/0001628280-24-047099.json
- Plain text: https://secwatch.observer/filing/0001628280-24-047099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.